Latest OBT Stories
OXFORD, England, January 25, 2011 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announces that sanofi-aventis has acquired an exclusive world-wide license to one of OBT's internal preclinical antibody programs. sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer.
OXFORD, England, December 9 /PRNewswire/ -- - Appointment Follows Recent Recruitment of Senior Antibody Industry Leaders and Highlights OBT's Growth Into a Leading Oncology-Focused Therapeutic Antibody Company Oxford BioTherapeutics (OBT) has today announced the appointment of Dr Michael Moore as non-executive Chairman.
OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.